• Positive efficacy and safety data of MaaT013 in aGvHD in the Compassionate Access Program presented at the EBMT 2024 Annual Conference with a gastrointestinal overall response rate (GI-ORR) of 63% at D28, an overall survival (OS) of 49% at one year and 42% at 18 months in patients similar to those included in the Phase 3 ARES clinical trial.
• The primary endpoint, GI-ORR at D28, of the ARES Phase 3 clinical trial in aGvHD is expected in mid-Q4 2024.
• Production of batches of MaaT013 intended for clinical supply in the United States.
• Participation in an investigator-sponsored, randomized, multicenter Phase 2 trial evaluating MaaT033 concomitantly with anti-PD1 therapy in patients with advanced lung cancer. This trial, promoted by the Gustave Roussy Institute which pilots cutting-edge research in the field of microbiota, is part of the IMMUNOLIFE program, a consortium comprising researchers and biotechnology companies.
• Completion of patient recruitment for the IASO Phase 1 clinical trial, evaluating MaaT033 in patients with amyotrophic lateral sclerosis (ALS).
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]